Funding
← Back to your selection

Hatteras Venture Partners

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$167M
2 disclosed · full round size, not this investor’s share

By stage

Series B1
Undisclosed1

By primary sector

AI1
Biotech1

By country

United States2

Rounds

2 in this selection
CREATE Medicines

Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies

$122MSeries B
Role not disclosed
Ten63 Therapeutics

Develops AI-driven drug discovery platform for first- and best-in-class therapeutics

$45MStrategic
Role not disclosed